NCT07461454 2026-03-10
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Not yet recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
CSPC Megalith Biopharmaceutical Co.,Ltd.